NephroGenex (OTCMKTS: NRXGQ) and Mylan (NASDAQ:MYL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Earnings and Valuation
This table compares NephroGenex and Mylan’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mylan||$11.08 billion||1.85||$480.00 million||$1.61||23.68|
This is a summary of current ratings and target prices for NephroGenex and Mylan, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NephroGenex currently has a consensus price target of $17.50, indicating a potential upside of 624,900.00%. Mylan has a consensus price target of $40.96, indicating a potential upside of 7.45%. Given NephroGenex’s stronger consensus rating and higher probable upside, equities research analysts clearly believe NephroGenex is more favorable than Mylan.
Insider & Institutional Ownership
73.9% of Mylan shares are held by institutional investors. 0.7% of Mylan shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares NephroGenex and Mylan’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
NephroGenex has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, Mylan has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
Mylan beats NephroGenex on 9 of the 11 factors compared between the two stocks.
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
Receive News & Ratings for NephroGenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.